Presidio Property Trust, Inc. (SQFT) - 10-Q Summary
Business Context and Reporting Period
Company: Presidio Property Trust, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: An internally managed REIT owning office, industrial, retail, and triple-net leased model home properties. As of September 30, 2025, the portfolio included 10 commercial properties and 84 model homes across multiple states. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics (Nine Months Ended Sept 30, 2025)
| Metric | 2025 (9 Months) | 2024 (9 Months) |
|---|---|---|
| Total Revenue | $12.70 million | $14.10 million |
| Net Loss (GAAP) | $(3.96) million | $(20.82) million |
| Net Loss Attributable to Common Stockholders | $(6.03) million | $(24.80) million |
| Net Operating Income (NOI) | $8.09 million | $9.45 million |
| Adjusted NOI (Model Homes) | $8.47 million | $12.40 million |
| Cash, Cash Equivalents & Restricted Cash | $8.00 million | $7.20 million |
| Total Mortgage Debt (Principal) | $94.64 million | $102.84 million |
| Weighted Average Interest Rate | 6.17% | 5.44% |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 10% year-over-year, primarily due to the February 2025 sale of two commercial properties (Union Town Center and Research Parkway) and a reduction in model home rental income.
- Improved Net Loss: Net loss improved significantly from $(20.82) million in 2024 to $(3.96) million in 2025. This improvement is largely driven by the absence of a $(17.82) million loss on Conduit Pharmaceuticals marketable securities recorded in the prior year.
- Asset Impairments: The company recorded $4.43 million in non-cash impairment charges for the nine months ended September 30, 2025. This includes a $3.3 million charge related to the Dakota Center property (held for sale) and a $0.9 million charge for the Shea Center II property.
- Debt Reduction: Total mortgage debt decreased by approximately $8.2 million, resulting from the payoff of loans associated with sold commercial properties.
- Stock Activity: The company completed a 1-for-10 reverse stock split in May 2025 and executed a tender offer in April 2025, repurchasing 214,412 shares of common stock for approximately $1.46 million.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing cash ($8.0 million), operating cash flows, and refinancing capabilities are sufficient to fund operations for the next 12 months. However, there is no assurance that refinancing will be available on acceptable terms.
- Dividends: The company continues to pay monthly dividends on Series D Preferred Stock ($0.19531 per share). No dividends were declared on Series A Common Stock for the nine months ended September 30, 2025.
- Debt Maturities: Significant principal payments are due in the coming year: approximately $10.4 million in late 2025 and $21.1 million in 2026. The Dakota Center loan (matured July 2024) is in default status, with a pending short sale expected in Q4 2025 to settle the non-recourse debt.
- Strategic Committee: A Strategic Planning and Cyber Committee was established in June 2024 to oversee business strategy and potential strategic alternatives, though no formal timetable for transactions has been set.
- Risks: Key risks include the inability to refinance maturing debt, potential delisting from Nasdaq, reliance on third-party property managers, and the impact of economic conditions on tenant creditworthiness and rental rates.
Investor Verification Checklist
- Dakota Center Sale: Verify the closing of the Dakota Center property sale in Q4 2025 and confirm the final payoff amount of the non-recourse loan to ensure no residual liability.
- Shea Center II Occupancy: Monitor leasing progress for the 31% of vacant space at Shea Center II following the Halliburton lease expiration to assess future NOI stability.
- Debt Refinancing: Track the company's ability to refinance the $16.4 million loan maturing in January 2026 (Shea Center II) and other model home loans maturing in 2025-2026.
- Conduit Pharmaceuticals Exposure: Confirm the complete exit from Conduit Pharmaceuticals equity positions and verify the current valuation of remaining warrants ($7,515).
- Common Stock Dividends: Review future board announcements regarding the potential resumption of quarterly dividends for Series A Common Stockholders.